Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ < sup > 177 < /sup > Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

CONCLUSION: We successfully implemented same-day post-therapy SPECT/CT after [177Lu]Lu-PSMA-617 infusions. Quantitation of 1-2 h post-therapy SPECT/CT images is a promising method for assessing treatment response. However, the approach is currently limited by its suboptimal detection of small tumor lesions and the necessity of incorporating a third-cycle SPECT/CT to mitigate the effects of any potential treatment-related flare-up. Further investigation in a larger patient cohort and prospective validation is essential to confirm these findings and to explore the role of SPECT/CT as a potential adjunct to PSMA PET/CT in managing mCRPC.PMID:38635050 | DOI:10.1007/s00259-024-06718-6
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research